235 related articles for article (PubMed ID: 12422304)
21. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
22. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
Ramanathan RK; Clark JW; Kemeny NE; Lenz HJ; Gococo KO; Haller DG; Mitchell EP; Kardinal CG
J Clin Oncol; 2003 Aug; 21(15):2904-11. PubMed ID: 12885808
[TBL] [Abstract][Full Text] [Related]
23. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
[TBL] [Abstract][Full Text] [Related]
26. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Gamelin E; Bouil AL; Boisdron-Celle M; Turcant A; Delva R; Cailleux A; Krikorian A; Brienza S; Cvitkovic E; Robert J; Larra F; Allain P
Clin Cancer Res; 1997 Jun; 3(6):891-9. PubMed ID: 9815764
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer.
Becouarn Y; Rougier P
Semin Oncol; 1998 Apr; 25(2 Suppl 5):23-31. PubMed ID: 9609105
[TBL] [Abstract][Full Text] [Related]
28. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
[TBL] [Abstract][Full Text] [Related]
29. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
[TBL] [Abstract][Full Text] [Related]
30. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
31. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Twelves C
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):23-6. PubMed ID: 12520636
[TBL] [Abstract][Full Text] [Related]
32. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
33. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin.
Gent P; Massey K
Int J Palliat Nurs; 2001 Jul; 7(7):354-9. PubMed ID: 11951404
[TBL] [Abstract][Full Text] [Related]
34. Oxaliplatin-induced immune pancytopenia.
Taleghani BM; Meyer O; Fontana S; Ahrens N; Novak U; Borner MM; Salama A
Transfusion; 2005 May; 45(5):704-8. PubMed ID: 15847658
[TBL] [Abstract][Full Text] [Related]
35. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
36. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
Lucchetta M; Lonardi S; Bergamo F; Alberti P; Velasco R; Argyriou AA; Briani C; Bruna J; Cazzaniga M; Cortinovis D; Cavaletti G; Kalofonos HP
Cancer Chemother Pharmacol; 2012 Dec; 70(6):899-902. PubMed ID: 23108696
[TBL] [Abstract][Full Text] [Related]
37. Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy.
Berretta M; Taibi R; Bearz A; La Mura N; Berretta S; Tirelli U; Frustaci S
J Chemother; 2004 Dec; 16(6):595-8. PubMed ID: 15700853
[TBL] [Abstract][Full Text] [Related]
38. Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review.
Pulvers JN; Marx G
Asia Pac J Clin Oncol; 2017 Dec; 13(6):345-355. PubMed ID: 28653815
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
